Downregulation of microRNA-1 and microRNA-145 contributes synergistically to the development of colon cancer

Xu,Xuehu; Wu,Xiaobing; Jiang,Qingping; Sun,Yan; Liu,Haibo; Chen,Rong; Wu,Shangbiao

doi:10.3892/ijmm.2015.2364

Downregulation of microRNA-1 and microRNA-145 contributes synergistically to the development of colon cancer

Authors:
- Xuehu Xu
- Xiaobing Wu
- Qingping Jiang
- Yan Sun
- Haibo Liu
- Rong Chen
- Shangbiao Wu
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China, Department of Pathology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China, Department of Gastroenterology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China
Published online on: October 9, 2015 https://doi.org/10.3892/ijmm.2015.2364
Pages: 1630-1638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify the differentially expressed microRNAs (miRNAs or miRs) in patients with colon cancer and examine their roles in the pathogenesis of the disease. The expression profiles of miRNAs were examined in tumor tissue samples collected from 20 patients with histologically confirmed colon cancer and in the adjacent non-cancerous control tissues using microarray analysis. We found that numerous miRNAs were differentially expressed in the colon cancer tissues compared with the control tissues. Following functional analysis, we noted that three miRNAs which were significantly downregulated, miR-145, miR-451 and miR-1, shared the same target gene, [NLR family, apoptosis inhibitory protein (NAIP)], which has previously been reported to be involved in the development of colon cancer. We then confirmed that NAIP is a target gene of miR-145 and miR-1, but not of miR-451, using a luceriferase assay, and we confirmed the expression patterns of these miRNAs and NAIP in the tumor tissue, as well as in the adjacent non-cancerous control tissues. Additionally, in order to examine the function of miR-145 and miR-1 in human colon cancer, we transiently transfected a human colon cancer cell line with miR-145 and miR-1 mimics or inhibitors, and the results of MTT assay revealed that the re-expression of miR-145 and miR-1 inhibited the survival of colon cancer cells, which may be attributed to the inhibition of the anti-apoptotic activity of NAIP. Our findings demonstrated that miR-145 and miR-1 play a negative regulatory role in the proliferation of colon cancer by targeting NAIP; thus, miR-145 and miR-1 may prove to be novel therapeutic targets in the treatment of colon cancer.

View Figures

View References

1	Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin. 53:5–26. 2003. View Article : Google Scholar : PubMed/NCBI
2	Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK and Monfardini S: FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res. 25:563–576. 2005.PubMed/NCBI
3	Goldberg RM and Gill S: Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 54(Suppl 1): S57–S64. 2004.PubMed/NCBI
4	Loeve F, van Ballegooijen M, Snel P and Habbema JD: Colorectal cancer risk after colonoscopic polypectomy: a population-based study and literature search. Eur J Cancer. 41:416–422. 2005. View Article : Google Scholar : PubMed/NCBI
5	Koehler A, Bataille F, Schmid C, Ruemmele P, Waldeck A, Blaszyk H, Hartmann A, Hofstaedter F and Dietmaier W: Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol. 204:65–74. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kolonel LN, Altshuler D and Henderson BE: The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer. 4:519–527. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ohtsuka M, Ling H, Doki Y, Mori M and Calin GA: MicroRNA processing and human cancer. J Clin Med. 4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang J, Song YX, Ma B, Wang JJ, Sun JX, Chen XW, Zhao JH, Yang YC and Wang ZN: Regulatory roles of non-coding RNAs in colorectal cancer. Int J Mol Sci. 16:19886–19919. 2015. View Article : Google Scholar : PubMed/NCBI
9	Anwar SL and Lehmann U: MicroRNAs: emerging novel clinical biomarkers for hepatocellular carcinomas. J Clin Med. 4:1631–1650. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kedmi M, Sas-Chen A and Yarden Y: MicroRNAs and growth factors: an alliance propelling tumor progression. J Clin Med. 4:1578–1599. 2015. View Article : Google Scholar : PubMed/NCBI
11	Han F, He J, Li F, Yang J, Wei J, Cho WC and Liu X: Emerging roles of nicroRNAs in EGFR-targeted therapies for lung cancer. Biomed Res Int. 2015:6727592015. View Article : Google Scholar
12	Croner RS, Foertsch T, Brueckl WM, Guenther K, Siebenhaar R, Stremmel C, Matzel KE, Papadopoulos T, Kirchner T, Behrens J, et al: Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis. 20:353–362. 2005. View Article : Google Scholar
13	Raetz EA and Moos PJ: Impact of microarray technology in clinical oncology. Cancer Invest. 22:312–320. 2004. View Article : Google Scholar : PubMed/NCBI
14	Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF and Li H: Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev. 14:437–443. 2005. View Article : Google Scholar : PubMed/NCBI
15	Nambiar PR, Nakanishi M, Gupta R, Cheung E, Firouzi A, Ma XJ, Flynn C, Dong M, Guda K, Levine J, et al: Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res. 64:6394–6401. 2004. View Article : Google Scholar : PubMed/NCBI
16	Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and Augenlicht LH: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63:8791–8812. 2003.PubMed/NCBI
17	Neviani P and Fabbri M: Exosomic microRNAs in the tumor microenvironment. Front Med (Lausanne). 2:472015.
18	Eisinger F, Roussel C, Morère JF and Viguier J: Cancer screening: reaching the limits or terra incognita? Lessons from the EDIFICE surveys. Eur J Cancer Prev. 20(Suppl 1): S42–S44. 2011. View Article : Google Scholar : PubMed/NCBI
19	Peters U, Bien S and Zubair N: Genetic architecture of colorectal cancer. Gut. 64:1623–1636. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut. 58:1375–1381. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan FK, Yu J and Sung JJ: Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 61:739–745. 2011. View Article : Google Scholar : PubMed/NCBI
23	Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ruddon R: Cancer Biology. Oxford University Press; New York, NY: 2007
25	Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, et al: Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
26	Chekulaeva M and Filipowicz W: Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol. 21:452–460. 2009. View Article : Google Scholar : PubMed/NCBI
27	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
28	Li J, Dong X, Wang Z and Wu J: MicroRNA-1 in cardiac Diseases and cancers. Korean J Physiol Pharmacol. 18:359–363. 2014. View Article : Google Scholar : PubMed/NCBI
29	Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, et al: Methylation mediated silencing of MicroRNA-1 gene and its role in hepato-cellular carcinogenesis. Cancer Res. 68:5049–5058. 2008. View Article : Google Scholar : PubMed/NCBI
30	Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y and Asakura A: MyoD regulates apoptosis of myoblasts through microRNA-mediated downregulation of Pax3. J Cell Biol. 191:347–365. 2010. View Article : Google Scholar : PubMed/NCBI
31	Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
32	Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa M: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011. View Article : Google Scholar : PubMed/NCBI
33	Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2:29–42. 2011. View Article : Google Scholar : PubMed/NCBI
34	Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L and Jiang BH: MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 40:761–774. 2012. View Article : Google Scholar :
35	Götte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, et al: miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 29:6569–6580. 2010. View Article : Google Scholar : PubMed/NCBI
36	Akao Y, Nakagawa Y, Iio A and Naoe T: Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk Res. 33:1530–1538. 2009. View Article : Google Scholar : PubMed/NCBI
37	Gao W, Yu Y, Cao H, Shen H, Li X, Pan S and Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
38	Clapé C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, Avancès C, Villalba M, Culine S and Fajas L: miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 4:e75422009. View Article : Google Scholar : PubMed/NCBI
39	Lee NP, Poon RT, Shek FH, Ng IO and Luk JM: Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta. 1806:138–145. 2010.PubMed/NCBI
40	Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, et al: Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 50:1453–1463. 2009. View Article : Google Scholar : PubMed/NCBI
41	Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK and Aigner A: MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 71:5214–5224. 2011. View Article : Google Scholar : PubMed/NCBI
42	Grzybowska-Izydorczyk O and Smolewski P: The role of the inhibitor of apoptosis protein (IAP) family in hematological malignancies. Postepy Hig Med Dosw (Online). 62:55–63. 2008.In Polish.
43	Herman MD, Moche M, Flodin S, Welin M, Trésaugues L, Johansson I, Nilsson M, Nordlund P and Nyman T: Structures of BIR domains from human NAIP and cIAP2. Acta Crystallogr Sect F Struct Biol Cryst Commun. 65:1091–1096. 2009. View Article : Google Scholar : PubMed/NCBI
44	Verhagen AM, Coulson EJ and Vaux DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2:reviews3009–reviews3009.10. 2001. View Article : Google Scholar : PubMed/NCBI
45	Davoodi J, Ghahremani MH, Es-Haghi A, Mohammad-Gholi A and Mackenzie A: Neuronal apoptosis inhibitory protein, NAIP, is an inhibitor of procaspase-9. Int J Biochem Cell Biol. 42:958–964. 2010. View Article : Google Scholar : PubMed/NCBI
46	Dubrez-Daloz L, Dupoux A and Cartier J: IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle. 7:1036–1046. 2008. View Article : Google Scholar : PubMed/NCBI
47	Franchi L, Eigenbrod T, Munoz-Planillo R and Nunez G: The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 10:241–247. 2009. View Article : Google Scholar : PubMed/NCBI
48	Pekow JR, Dougherty U, Mustafi R, Zhu H, Kocherginsky M, Rubin DT, Hanauer SB, Hart J, Chang EB, Fichera A, et al: miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 18:94–100. 2012. View Article : Google Scholar